Edward Alan Copelan

11.4k citations

256 papers · 9.0k · 1 hit paper · h-index 43

Impact in

Hematology top 0.1%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 0.5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Hematology 183
- Hematopoietic Stem Cell Transplantation 118
- Acute Myeloid Leukemia Research 94
- Chronic Myeloid Leukemia Treatments 35
- Multiple Myeloma Research and Treatments 24
Genetics 58
- Myeloproliferative Neoplasms: Diagnosis and Treatment 29
- Chronic Lymphocytic Leukemia Research 23

Co-authors: Matt E Kalaycio (68 shared papers)Brian James Bolwell (68 shared papers)Ronald M. Sobecks (79 shared papers)Hillard Michael Lazarus (11 shared papers)Lisa A Rybicki (54 shared papers)Belinda Rene Avalos (58 shared papers)Daniel Jordan Weisdorf (9 shared papers)Robert M. Dean (52 shared papers)
Journals: Blood (66 papers)Transplantation and Cellular Therapy (50 papers)Bone Marrow Transplantation (30 papers)British Journal of Haematology (12 papers)Blood Advances (10 papers)
Partner nations: United States Australia Canada

In The Last Decade

Edward Alan Copelan

241 papers receiving 8.8k citations

Edward Alan Copelan's Hit Papers

align trajectories log scale

Hematopoietic Stem-Cell Transplantation 2006 · 2.0k citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2006 New England Journal of Medicine

Peers

Countries citing papers authored by Edward Alan Copelan

Since Specialization

Citations

This map shows the geographic impact of Edward Alan Copelan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Alan Copelan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Alan Copelan more than expected).

Fields of papers citing papers by Edward Alan Copelan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Alan Copelan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Alan Copelan. The network helps show where Edward Alan Copelan may publish in the future.

Co-authors

The 25 scholars most cited alongside Edward Alan Copelan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Edward Alan Copelan Line = papers co-authored together Edward Alan Copelan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 256 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Hematopoietic Stem-Cell Transplantation New England Journal of Medicine ·Edward Alan Copelan Hit paper breakdown →	2006	2036
2	Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure Journal of Clinical Oncology ·Michel Duval, John P. Klein, Wensheng He, Jean‐Yves Cahn, Mitchell Stuart Cairo, Bruce Matthew Camitta, Rammurti T. Kamble, Edward Alan Copelan	2010	370
3	Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations Transplantation and Cellular Therapy ·Sergio Giralt, Luciano Jose Costa, Jeffrey R. Schriber, John F. DiPersio, Richard Thomas Maziarz, John Michael McCarty, Paul J. Shaughnessy, Edward L. Snyder	2013	311
4	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms Leukemia ·Fabı́ola Traina, Valeria Visconte, Paul J. Elson, Ali Tabarroki, Ania Jankowska, Edy Hasrouni, Yuka Sugimoto, Hadrian Szpurka	2013	252
5	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States Blood ·Lori S. Muffly, Marcelo Pasquini, Michael J. Martens, Ruta Brazauskas, Xiaochun Zhu, Kehinde Adekola, Mahmoud Deeb Aljurf, Karen Kuhn Ballen	2017	239
6	Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS Bone Marrow Transplantation ·Selina M. Luger, Olle T.H. Ringdén, M-J Zhang, Waleska S. Pérez, Michael Russell Bishop, Martin Bornhäuser, Christopher Bredeson, Mitchell Stuart Cairo	2011	236
7	Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients Blood ·Mikkael Aaron Sekeres, Paul J. Elson, Matt E Kalaycio, Anjali S. Advani, Edward Alan Copelan, Stefan H Faderl, Hagop Kantarjian, Elihu H. Estey	2008	172
8	The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first and second complete remission Blood ·David Ian Marks, Tao Wang, Waleska S. Pérez, Joseph H. Antin, Edward Alan Copelan, Robert Peter Gale, Biju George, Vikas Gupta	2010	172
9	A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing Sibling Allografting for Acute Lymphoblastic Leukemia in First or Second Complete Remission Transplantation and Cellular Therapy ·David Ian Marks, Stephen J. Forman, Karl G. Blume, Waleska S. Pérez, Daniel Jordan Weisdorf, Armand Keating, Robert Peter Gale, Mitchell Stuart Cairo	2006	161
10	SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes Blood ·Valeria Visconte, Heesun Joyce Rogers, Jarnail Singh, John Barnard, Manoj Bupathi, Fabı́ola Traina, James Tanner McMahon, Hideki Makishima	2012	153
11	Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis Blood ·Vikas Gupta, Martin S. Tallman, Wensheng He, Brent R. Logan, Edward Alan Copelan, Robert Peter Gale, Hanna Jean Khoury, Thomas R. Klumpp	2010	151
12	Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI Blood ·Edward Alan Copelan, Betty K. Hamilton, Belinda Rene Avalos, Kwang Woo Ahn, Brian James Bolwell, Xiaochun Zhu, Mahmoud Deeb Aljurf, Koen van Besien	2013	139
13	A Scheme for Defining Cause of Death and Its Application in the T Cell Depletion Trial Transplantation and Cellular Therapy ·Edward Alan Copelan, James T. Casper, Shelly L. Carter, Jo‐Anne H. van Burik, David Duane Hurd, Adam M. Mendizabal, John E. Wagner, Saul Yanovich	2007	137
14	Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease Leukemia ·Veronika Bachanová, Dan Marks, M-J Zhang, Hai‐Lin Wang, Marcos J. G. De Lima, Mahmoud Deeb Aljurf, Martha Lucia Arellano, Andrew S. Artz	2013	112
15	Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia Blood ·Stephanie J. Lee, Manisha Kamal Kukreja, Tao Wang, Sergio Giralt, Jeff Szer, Mukta Arora, Ann E. Woolfrey, Francisco Cervantes	2008	109
16	Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission Transplantation and Cellular Therapy ·Sherif Shafik Farag, Kati S. Maharry, Mei Zhang, Waleska S. Pérez, Stephen L. George, Krzysztof Mrózek, John F. DiPersio, Donald Werner Bunjes	2011	105
17	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis Transplantation and Cellular Therapy ·Carla Casulo, Jonathan W. Friedberg, Kwang Woo Ahn, Christopher R. Flowers, Alessandro Digilio, Sonali M. Smith, Sairah Ahmed, David James Inwards	2017	99
18	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission Blood Advances ·Armin Rashidi, Mehdi Hamadani, Mei Zhang, Hai-Lin Wang, Hisham Abdel‐Azim, Mahmoud Deeb Aljurf, Amer Assal, Ashish R. Bajel	2019	99
19	Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis PLoS ONE ·Fabı́ola Traina, Valeria Visconte, Anna Maria Jankowska, Hideki Makishima, Christine L. O’Keefe, Paul J. Elson, Yingchun Han, Fred H. Hsieh	2012	97
20	Elevated pretransplant ferritin is associated with a lower incidence of chronic graft‐versus‐host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation British Journal of Haematology ·Anuj Kumar Mahindra, Brian James Bolwell, Ronald M. Sobecks, Lisa A Rybicki, Brad L. Pohlman, Robert M. Dean, Steve Andresen, John William Sweetenham	2009	86

About Edward Alan Copelan

Edward Alan Copelan is a scholar working on Hematology, Genetics, Oncology, Public Health, Environmental and Occupational Health and Pathology and Forensic Medicine, having authored 256 papers that have together received 9.0k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (118 papers), Acute Myeloid Leukemia Research (94 papers), Acute Lymphoblastic Leukemia research (63 papers), Chronic Myeloid Leukemia Treatments (35 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (29 papers), Multiple Myeloma Research and Treatments (24 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Polyomavirus and related diseases (21 papers). The work is most often cited by research in Hematology (6.0k citations), Genetics (1.5k citations), Transplantation (286 citations), Oncology (1.9k citations) and Public Health, Environmental and Occupational Health (2.0k citations). Edward Alan Copelan has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Matt E Kalaycio, Brian James Bolwell, Ronald M. Sobecks, Hillard Michael Lazarus, Lisa A Rybicki, Belinda Rene Avalos, Daniel Jordan Weisdorf, Robert M. Dean, Mikkael Aaron Sekeres and Brad L. Pohlman. Their work appears in journals such as Blood, Transplantation and Cellular Therapy, Bone Marrow Transplantation, British Journal of Haematology and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Edward Alan Copelan

Impact in

Papers in i

In The Last Decade

Edward Alan Copelan

Edward Alan Copelan's Hit Papers

Peers

Countries citing papers authored by Edward Alan Copelan

Fields of papers citing papers by Edward Alan Copelan

All Works

About Edward Alan Copelan

Explore authors with similar magnitude of impact

Papers in